Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | DRD4 | P21917 | 3/20 | 0.30 |
| ▸ | DRD3 | P35462 | 3/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779865 | 0.88 | — | — | |
| SCHEMBL26362395 | 0.77 | DRD2 (0.34) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL26365812 | 0.77 | MEN1 (0.33) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL11983399 | 0.74 | BRD4 (0.36) | GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL26121565 | 0.73 | MEN1 (0.33) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL31446922 | 0.72 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1KMT2ATDP1 | |
| SCHEMBL20503156 | 0.70 | GAA (0.33) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL12179302 | 0.68 | — | — | |
| SCHEMBL26584152 | 0.68 | GAA (0.32) | GAASMN1; SMN2MEN1KMT2ADRD2 | |
| SCHEMBL23660705 | 0.68 | GAA (0.34) | GAASMN1; SMN2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | GAA 3210/4885SMN1; SMN2 3396/4885HRH3 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.